AN OPEN-LABEL, EXTENSION (ROLLOVER)STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Vemurafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 13 Feb 2018 Planned End Date changed from 28 Feb 2019 to 24 Jun 2020.
- 13 Feb 2018 Planned primary completion date changed from 28 Feb 2019 to 31 Dec 2019.